A Randomized Phase II Study of Neoadjuvant PD-1 Blockade Alone or Plus TPF Induction Chemotherapy for Resectable Local Advanced Oral Squamous Cell Carcinoma
Phase: PHASE2
Conditions: Oral Squamous Cell Carcinoma
Sponsor: Hospital of Stomatology, Wuhan University

1 
 
Clinical trial protocol information 
Study Title: Neoadjuvant PD-1 Blockade in Resectable Oral Squamous Cell 
Carcinoma  
Official Title: A Randomized Phase Ⅱ Study of Neoadjuvant PD-1 Blockade Alone or 
Plus TPF Induction Chemotherapy for Resectable Local Advanced Oral Squamous Cell 
Carcinoma 
 
 
 
 
 
 
 
 
NCT registration number：  NCT04649476                             
Center： Hospital of Stomatology, Wuhan University                      
Supplied agents： Camrelizumab, Jiangsu HengRui Medicine Co., Ltd      
Principal investigator： Gang Chen, Professor                           
Date：  3/25/2022                                                   
Protocol version：1.2                                                

2 
 
Contents 
Study title: Neoadjuvant PD-1 blockade in resectable oral squamous cell carcinoma……………..1 
Contents ............................................................................................................................................ 2 
1. Background and rational ............................................................................................................... 4 
1.1. Background ........................................................................................................................ 4 
1.2. Cancer immunotherapy ...................................................................................................... 5 
1.3. Expressions of PD-L1 in human ........................................................................................ 6 
1.4. Research of recurrent or metastatic head and neck squamous cell carcinoma ................... 6 
1.5. Treatment of local advanced OSCC ................................................................................... 6 
1.6. Rational for preoperative neoadjuvant immunotherapy in OSCC ..................................... 7 
1.7. Clinical trials of immunotherapy in OSCC ........................................................................ 7 
1.8. Development of Camrelizumab ......................................................................................... 7 
1.9. Clinical experience with Camrelizumab ............................................................................ 8 
2. Purpose .......................................................................................................................................... 8 
3. Objective ....................................................................................................................................... 9 
3.1. Primary endpoint ................................................................................................................ 9 
3.2. Secondary endpoint ............................................................................................................ 9 
3.3. Exploratory endpoint .......................................................................................................... 9 
4. Study design and treatment plan ................................................................................................... 9 
4.1. Recruitment ........................................................................................................................ 9 
4.2. Determination of Eligibility ............................................................................................. 10 
4.3. Study design and toxicity assessments ............................................................................. 10 
4.4. Diagnostic and surgical evaluation .................................................................................. 11 
4.5. Adjuvant therapy .............................................................................................................. 12 
4.6. Perioperative safety assessment ....................................................................................... 13 
5. Laboratory research..................................................................................................................... 13 
5.1. Tissue specimen ............................................................................................................... 13 
5.2. Handling of biopsy specimen ........................................................................................... 13 
5.3. Handling of surgical tumor specimen .............................................................................. 14 
5.4. Handling of blood ............................................................................................................ 14 
5.5. Handling of saliva ............................................................................................................ 14 
6. Screening and discontinued /withdrawal .................................................................................... 14 
6.1. Inclusion criteria .............................................................................................................. 14 
6.2. Exclusion Criteria ............................................................................................................ 15 
6.3. Withdrawal from study ..................................................................................................... 15 
7. Study procedures ......................................................................................................................... 16 
7.1. Clinical operation schedule .............................................................................................. 16 
7.2. Specimen processing schedule ......................................................................................... 19 
8. Study drug ................................................................................................................................... 20 
8.1. Drug description ............................................................................................................... 20 
8.2. Pharmacokinetics of camrelizumab ................................................................................. 21 
8.3. Safety summary and side effects of camrelizumab .......................................................... 21 
8.4. Disposal and distribution of camrelizumab ...................................................................... 21 

3 
 
8.5. Injection method of camrelizumab ................................................................................... 22 
8.6. Destruction of research drugs ........................................................................................... 22 
9. Safety evaluation ......................................................................................................................... 22 
9.1. Safety summary ................................................................................................................ 22 
9.2. Adverse event ................................................................................................................... 23 
9.3. Sorting and reporting of serious adverse events ............................................................... 24 
9.4. Non-serious adverse events .............................................................................................. 24 
9.5. Abnormal laboratory test results ...................................................................................... 25 
9.6. Gestation .......................................................................................................................... 25 
9.7. Overuse ............................................................................................................................ 25 
9.8. Other safety precautions ................................................................................................... 26 
10. Effectiveness evaluation ............................................................................................................ 26 
11. Exploratory study ...................................................................................................................... 26 
11.1. Tissue and body fluid analysis........................................................................................ 26 
11.2. Screening of immune response markers for anti-PD-1 therapy ..................................... 27 
11.3. Indicators to be detected ................................................................................................. 27 
12. Management of adverse events ................................................................................................. 28 
12.1. Infusion reaction ............................................................................................................ 28 
12.2. Immune-related adverse events ...................................................................................... 29 
13. Research Management .............................................................................................................. 34 
13.1. Amendments to the Scheme ........................................................................................... 34 
13.2. Informed Consent ........................................................................................................... 34 
13.3. Code of Ethics and Practice for the Management of Drug Clinical Trials ..................... 34 
13.4. Regulatory authorities .................................................................................................... 35 
13.5. Principal Investigator (PI) Responsibilities .................................................................... 35 
14. Data Management and Security Controls.................................................................................. 35 
14.1. Data collection ............................................................................................................... 35 
14.2. Data curation .................................................................................................................. 36 
14.3. Discussion Meetings ...................................................................................................... 36 
14.4. Quality Control .............................................................................................................. 37 
15. Statistical analysis plan ............................................................................................................. 37 
15.1. Study design ................................................................................................................... 37 
15.2. Data Analysis Plan ......................................................................................................... 38 
16. Prospective research plan .......................................................................................................... 39 
17.Informed consent……………………………………………………………………………… 40 
References ....................................................................................................................................... 42 
 
 
 
 
 
 

4 
 
1. Background and rational 
1.1Background 
Oral squamous cell carcinoma (OSCC) is the most common malignant tumor in the oral and 
maxillofacial region, with a high incidence and a poor prognosis. The 5-year survival rate of patients 
with OSCC is about 50%. Among them, local advanced patients have a lower 5-year survival rate, 
only about 30%, due to high tumor burden, recurrence and metastasis. Currently, radical surgery 
combined with postoperative radiotherapy or chemoradiotherapy is the main treatment for local 
advanced OSCC, but its effect is not ideal. In recent years, researchers have tried the treatment of 
TPF induction chemotherapy (Docetaxel-cisplatin-5-fluorouracil) for patients with local advanced 
OSCC, but these results failed to increase the 5-year overall survival rate. Therefore, how to improve 
the treatment effect for patients with local advanced OSCC is a major challenge currently faced by 
oral and maxillofacial-head and neck tumor surgeons. 
In recent years, the rapid rise of immunotherapy that won the 2018 Nobel Prize has brought 
hope to patients with advanced cancer. Among them, PD-L1/PD-1 blockade is currently a 
representative drug for tumor immunotherapy. It has been proven to have a significant and long-
lasting effect in the treatment of patients with recurrent or metastatic malignant melanoma, lung 
cancer and head and neck squamous cell carcinoma who have lost the opportunity for surgery. 
What’s more, the results of two clinical trials recently completed also suggest that the effect is much 
surprising if PD-1 monoclonal antibody is used as neoadjuvant immunotherapy for operable 
malignant tumors. Forde et al. performed two cycles of PD-1 monoclonal antibody neoadjuvant 
immunotherapy on patients with operable non-small cell lung cancer before surgery, and found that 
45% (9/20) of the patients had pathological remission, and 3 of them had complete Pathological 
remission, and only 15% of patients have recurrence or metastasis 1 year after surgery, and the 
overall survival rate is as high as 90%. At the same time, Huang et al. treated patients with stage 
III/IV operable malignant melanoma with one PD-1 monoclonal antibody treatment before surgery, 
which resulted in 30% (8/27) patients with complete or overall pathological remission. The annual 
progression-free survival rate was 63%, and the overall two-year survival rate reached 93%. Taken 
together, PD-1 blockade is very promising as a neoadjuvant treatment to improve the efficacy of 
operable local advanced OSCC patients. 

5 
 
Of note, immunotherapy is not effective for every patient, less than 30% of patients can benefit 
from PD-1 blockade, whether it is used for the treatment of inoperable recurrent or metastatic tumors 
or for the preoperative adjuvant treatment of operable tumors. Therefore, further elucidating the 
precise regulation mechanism of tumor immune escape, exploring the molecular mechanism of 
immunotherapy tolerance, and finding biomarkers that can predict the efficacy in an early stage are 
important for achieving precise tumor immunotherapy and effectively prolonging the survival time 
and improving the quality of life of patients with malignant tumors. Our research has found that 
tumor cells can exert immunosuppressive effects by secreting PD-L1+ extracellular vesicles. More 
importantly, the concentration level of PD-L1+ extracellular vesicles in the peripheral blood of 
patients with metastatic malignant melanoma and its change trend and amplitude in the early stage 
of immunotherapy can effectively evaluate the patient’s treatment effect. Based on the above 
research, we propose a liquid biopsy strategy based on the level of circulating PD-L1+ extracellular 
vesicles in the peripheral blood of tumor patients to predict the effectiveness of immunotherapy, 
which provides a fast and accurate method for early prediction of the efficacy of tumor 
immunotherapy. It has obvious advantages when compared with traditional tissue biopsy. At present, 
the research results have applied for international invention patents. However, whether this liquid 
biopsy strategy based on extracellular vesicles can be used to predict the efficacy of neoadjuvant 
immunotherapy, especially when used in the treatment of patients with local advanced OSCC, 
remains to be studied. 
1.2 Cancer immunotherapy 
Cancer immunotherapy is to restore the body's normal tumor immune response by 
reinvigorating the tumor-immune cycle, so as to achieve the purpose of eliminating tumors. Cancer 
immunotherapy mainly include monoclonal antibody immune checkpoint inhibitors (CTLA-4 
inhibitors, PD-1/PD-L1 inhibitors, etc.), therapeutic antibodies (anti-CD20 monoclonal antibodies, 
anti-CD30 monoclonal antibodies, anti-Her2 monoclonal antibodies, etc.), cancer vaccines, cell 
therapy (CAR-T therapy, etc.) and small molecule inhibitors, etc. Among them, PD-1/PD-L1 
inhibitors are currently the most studied and fastest-growing immunotherapy. Immune checkpoint 
inhibitors. Since the US FDA approved the first PD-1 inhibitor Keytruda (Pembrolizumab) for the 
treatment of malignant melanoma in 2014, there have been many PD-1/PD-L1 inhibitors in the 

6 
 
market. The indications involve non-small cell lung cancer, melanoma, renal cell carcinoma, 
urothelial carcinoma, Hodgkin’s lymphoma, hepatocellular carcinoma, advanced head and neck 
squamous cell carcinoma, etc. At present, the FDA has approved Pembrolizumab, Nivolumab, 
Atezolizumab, Duralumab, Avelumab, etc. for clinical treatment, and domestic PD-1/PD-L1 
inhibitors such as Camrelizumab, Sintilimab, Toripalimab, etc. 
In the current clinical trials, PD-1/PD-L1 inhibitors show obvious effects in patients with 
advanced unresectable malignant tumors, and many studies have confirmed that they are used as 
neoadjuvant immunotherapy in the local advanced stages. 
1.3 Expressions of PD-L1 in human 
Constitutive PD-L1 expression is normally limited to macrophage-lineage cells, although 
expression of PD-L1 can be is generally expressed in cells of the macrophage cell line. When 
malignant tumors appear, PD-L1 is expressed in most malignant tumor cells. The expression of PD-
L1 in patients with OSCC is related to the depth of tumor invasion, which further suggests that the 
expression of PD-L1 is related to tumor invasion and metastasis. Although there is still some 
controversy as to whether the expression of PD-L1 can evaluate the prognosis of OSCC, it has been 
confirmed that PD-L1 is related to poor prognosis in other tumor models. 
1.4 Research of recurrent or metastatic head and neck squamous cell carcinoma 
Nivolumab and Pembrolizumab have been approved for the treatment of recurrent or metastatic 
head and neck squamous cell carcinoma (R/MHNSCC). The clinical trial of Pembrolizumab 
(NCT01848834) confirmed that the overall response rate of imaging examination was 18%, and the 
patients could well tolerate the side effects. In another phase 3 clinical trial of R/MHNSCC 
(NCT02105636), the overall survival of patients treated with Nivolumab was longer than those with 
standard of care (7.5 months versus 5.5 months), and the one-year survival rate was also 
significantly improved (36.0% versus 16.6%) ), the incidence of serious side effects of grade 3 to 4 
is relatively low (13.1% versus 35.1%). 
1.5 Treatment of local advanced OSCC 
At present, surgical resection combined with postoperative adjuvant treatment is still the main 
treatment for local advanced OSCC. Though surgical skills and radiotherapy and chemotherapy 
techniques have made great progress in the past 2 decades, the five-year survival rate of patients 

7 
 
with OSCC remains between 50% and 60%. In view of the high recurrence rate and metastasis rate, 
TPF inductive chemotherapy had been applied for local advanced OSCC, but the results show that 
it cannot effectively improve the survival rate of patients. The NCCN guidelines point out that for 
patients with local advanced OSCC, in addition to conventional treatment, it is recommended to 
conduct clinical trials to explore better treatment options. 
1.6 Rational for preoperative neoadjuvant immunotherapy in OSCC 
The main purpose of preoperative neoadjuvant immunotherapy for OSCC is to eliminate 
residual imaging and invisible lesions after surgical resection, and to prevent recurrence or 
metastasis caused by deep infiltration or scattered micro-metastasis. However, after a major surgical 
trauma, the patient's general condition is more difficult to tolerate the side effects of adjuvant therapy. 
On the other hand, it is difficult for chemotherapy drugs to enter the tumor microenvironment 
through the blood supply. Neoadjuvant immunotherapy can solve these problems. What’s more, 
there are literature reports confirming that PD-1/PD- L1 inhibitors can reduce the pathological stage 
of tumors and bring better prognostic effects to patients. 
1.7 Clinical trials of immunotherapy in OSCC 
Oral squamous cell carcinoma has been shown to be an immunosuppressive disease. Studies 
have found that there is a decrease in infiltrating lymphocytes in oral squamous cell carcinoma, 
while inhibitory regulatory T-cell proliferation promotes tumor immune escape. Disruption of the 
function and antigen presentation capacity of natural killer cells is a manifestation of impaired 
immune cell function. The expression of PD-L1 in tumor tissues has a close relationship with the 
depth of tumor invasion and lymph node metastasis, and the depth of tumor infiltration and lymph 
node metastasis are closely related to the patient's poor prognosis. 
Ferris et al, studied PD-1 inhibitors for recurrent head and neck squamous cell carcinoma. The 
result showed that PD-1 inhibitors achieved satisfactory results compared with cisplatin 
chemotherapy. PD-1 inhibitors significantly improved overall survival and one-year survival, and 
the incidence of serious adverse events was also found to be lower in patients treated with PD-1 
inhibitors than in patients treated with cisplatin chemotherapy. 
1.8 Development of Camrelizumab 
Camrelizumab is a high-affinity IgG4 (kappa) anti-programmed cell death 1 (PD-1) 

8 
 
monoclonal antibody. By competing with PD-L1 or PD-L2 to bind PD-1 molecules to block the PD-
1/PD-L1 axis signaling pathway to increase tumor antigen-specific T cells and restart the tumor-
immune cycle. After a single injection of different doses of Camrelizumab, the T cell receptor 
binding rates of subjects at 60, 200, and 400 mg doses were 81%, 85%, and 88%, respectively. 
Since the first phase I clinical trial in Australia in 2015, the research of Camrelizumab on 
Hodgkin’s lymphoma, B cell lymphoma, esophageal squamous cell carcinoma, gastric-esophageal 
junction cancer, liver cancer has been launched in the Cancer Hospital of the Chinese Academy of 
Medical Sciences, the Cancer Center of Sun Yat-sen University, and Peking University Cancer 
Hospital. 
1.9 Clinical experience with Camrelizumab 
The results of 9 clinical trials published by Jiangsu HengRui Medicine Co., Ltd show that the 
immune-related adverse event (irAE) rate is 97%, most of the irAEs are mild to moderate including 
skin reactions, fever, hypothyroidism, fatigue, cough, and decreased appetite. 24% of subjects have 
irAEs ≥ grade 3. The overall adverse reaction is slighter than conventional chemotherapy. In a phase 
II clinical trial of patients with relapsed/refractory classic Hodgkin’s lymphoma who failed of two 
or more systemic treatments, the subjects are scheduled to be injected with Camrelizumab every 
two weeks. The response rate is 31.8%. In another study of nasopharyngeal carcinoma treated with 
Camerelizumab alone or plus gemcitabine and cisplatin, both treatments show satisfactory results. 
In Camerelizumab group, the overall progression rate is 34%, and the half-year progression-free 
survival rate is 48.2%. In Camrelizumab plus gemcitabine and cisplatin group, in which the subjects 
are treated with 6 courses of 200 mg of Camrelizumab, 1 g/m2 of gemcitabine, and 80 mg/m2 of 
cisplatin and followed by 200 mg of Camrelizumab, the overall progression rate is 91% and half-
year progression-free survival rate is 86.4%. The above results indicate that Camrelizumab is safe 
as well as feasible. 
2. Purpose 
The purpose of this study is to investigate the safety and feasibility of neoadjuvant PD-1 
blockade alone or neoadjuvant PD-1 blockade plus TPF induction chemotherapy in subjects with 
resectable local advanced OSCC. And on this basis, we will explore the changes of the profiles and 
functions of immune cells within tumors, lymph nodes and peripheral blood after the experimental 

9 
 
interventions, as well as their correlation with the patients’ response and prognosis. 
3. Objective 
3.1 Primary endpoint 
To investigate the pathologic response of resected tumors and lymph nodes to neoadjuvant PD-
1 blockade alone or neoadjuvant PD-1 blockade plus TPF induction chemotherapy. 
3.2 Secondary endpoint 
To investigate the clinical response of tumors and lymph nodes to neoadjuvant PD-1 blockade 
alone or neoadjuvant PD-1 blockade plus TPF induction chemotherapy, as evaluated by 
radiographic examinations and defined by RECIST 1.1. 
To investigate the two-year event-free survival (EFS) on each treatment group. EFS is the time 
from the date of randomization to the date of first record of disease progression as defined by 
RECIST 1.1. 
To investigate the two-year overall survival on each treatment group. 
To investigate the irAE rate. Number of participants experiencing any sign, symptom, disease, 
or worsening of preexisting conditions temporally associated with the experimental interventions or 
irrespective of the experimental interventions. 
3.3 Exploratory endpoint 
3.3.1To explore the changes of the profiles and functions of immune cells within tumors, lymph 
nodes and peripheral blood after the experimental interventions, as well as their correlation with the 
patients’ response and prognosis. 
3.3.2To evaluate the changes of the profiles and functions of extracellular vesicles within 
tumors, saliva and peripheral blood after the experimental interventions, as well as their correlation 
with the patients’ response and prognosis. 
3.3.3To investigate the sensitivity and specificity of specific subsets of extracellular vesicles 
in saliva or peripheral blood of patients and their key biomolecules as liquid biopsy markers to 
predict the efficacy of neoadjuvant therapy or to dynamically monitor its efficacy. 
4. Study design and treatment plan 
4.1 Recruitment 
Subjects will be recruited through the Department of Oncology, Wuhan University 

10 
 
Stomatological Hospital after being approved by the Ethics Committee of Wuhan University 
Stomatological Hospital and completing the procedures of clinical trial platform registration and 
Hubei Provincial Health Commission registration. Each subject will be assigned an ordered trial 
number (A-001, A-002, etc.) randomized into two groups by the electronic data acquisition system. 
4.2 Determination of Eligibility 
After eligibility is established, the study staff will register participants. The following are 
required to be submitted for successful registration: 
a) Registration form; 
b) Copy of informed consent; 
c) Copy of pathological diagnosis report; 
d) CT or PET/CT report, copies of chest CT and ECT; 
e) Copy of clinical data: 
-Routine blood examination including hemoglobin, red blood cell count, white blood cell count, 
granulocyte count, lymphocyte count, platelet count; 
-Blood biochemistry including alkaline phosphatase, urea nitrogen, creatinine, fasting blood 
glucose, potassium, sodium, and chlorine; 
-Hepatitis B virus surface antigen, hepatitis B surface antibody, hepatitis B e antigen, hepatitis 
B e antibody, hepatitis B core antibody; 
-Serum thyroid hormone determination: Thyroid-stimulating hormone (TSH), patients with 
endocrine abnormalities should receive care or additional examinations according to the normal 
program. 
4.3 Study design and toxicity assessments 
4.3.1 Study design and sample collection 
This study is a single-center, dual-arm, randomized open clinical trial, which will be conducted 
in the Department of Oral and Maxillofacial-Head and Neck Tumor Surgery, Wuhan University 
Stomatological Hospital. 68 people will be enrolled in this trial, and the subjects included are mainly 
from the oral and maxillofacial-head and neck tumor surgery. 68 Subjects will be randomly and 
averagely divided into two groups, Camrelizumab alone group (hereinafter referred to as the single 
group) and Camrelizumab plus TPF chemotherapy group (hereinafter referred to as the combined 

11 
 
group): 
Single group: Camrelizumab injection, surgical resection, radiotherapy/chemoradiotherapy. 
Combined group: Camrelizumab injection plus TPF induction chemotherapy, surgical 
resection, radiotherapy/chenmoradiotherapy. 
For Camrelizumab injection, subjects will receive 200 mg Camrelizumab each 2-week cycle 
for 3 cycles prior to surgery. And for TPF induction chemotherapy, subjects will receive 75 mg/m2 
docetaxel (T), 75 mg/m2 cisplatin (P) and 750 mg/m2 5-Fluorouracil (F) each 3-week cycle for 2 
cycles. 
Serial blood and saliva collection of the subjects will be performed prior to each 
Camerelizumab injection, once prior to surgery, once prior to radiotherapy, and each follow-up. 
Preoperative tumor biopsy and postoperative tumor lesion will be obtained for further study. The 
tissue biopsy specimens should be of a certain size to meet the volume requirements of rapid frozen 
examination and genomic analysis. The surgically resected specimen should contain tumor tissue 
and normal mucosa adjacent to the tumor. If there is cervical lymph node metastasis, it should 
contain cervical lymph nodes. The tissue should be embedded and fixed as soon as possible, or 
frozen in liquid nitrogen for subsequent analysis. 
4.3.2 Toxicity assessments 
Researchers will evaluate the safety of the subjects' toxicity from the start of the injection to 
90 days following the last dose of Camrelizumab. No dose delays due to toxicity will be permitted 
for patients enrolled on this study. If toxic side effects occur after the first injection of the drug and 
the patient cannot receive the second injection on time, the patient will begin to undergo surgical 
evaluation and begin subsequent treatment. Before surgery, make sure that the patient is in a irAE 
grade ≤ 1. 
4.4 Diagnostic and surgical evaluation 
4.4.1 Diagnostic evaluation and pre-surgical workup 
Subjects should obtain tissue biopsy to determine the nature of the disease before receiving 
drug treatment, and the specimen for tissue biopsy should be of a certain size to meet the volume 
requirements for rapid freezing examination and genomic analysis at the same time. 
The surgically resected specimen should include tumor tissue and normal mucosa adjacent to 

12 
 
the tumor. If there is cervical lymph node metastasis, the cervical lymph node should be included. 
Tissue should be embedded and fixed as soon as possible, or frozen in a liquid nitrogen tank for 
subsequent analysis. 
4.4.2 Diagnostic evaluation and pre-surgical workup 
All subjects included in the experimental study must be patients with clinical stage III to IVb 
OSCC. The patient will undergo imaging tests before surgery to assess the progression of the disease 
and the possibility of surgical resection. The surgeon or anesthesiologist evaluates the risk of surgery 
based on the patient's examination report within 7 days before surgery. Surgery for patients enrolled 
on this protocol will be according to generally accepted standards of care. 
4.4.3 Principle of surgery 
Tumor resection should strictly follow the NCCN Head and Neck Cancer Guidelines (Second 
Edition, 2018) for the resection of the primary oral squamous cell carcinoma and neck lymph node 
dissection, and follow-up treatment based on the results of surgery and pathological examination 
(Figure 1). 
 
Fig 1. NCCN guideline, version 2, 2018. Cancer of the oral cavity. 
4.5 Adjuvant therapy 
4.5.1 Postoperative radiotherapy 
All subjects will receive postoperative adjuvant radiotherapy within 4-6 weeks after surgery. 
Radiotherapy should be started as soon as possible for patients with high risk of recurrence, unless 
the patient's general condition is poor and cannot tolerate radiotherapy. Even if the wound is partially 
healed, the skin flap is poorly healed and the tracheal intubation or nasogastric tube is not removed, 

13 
 
the radiotherapy time should not be postponed, so as not to affect the prognosis. The dose of 
radiotherapy should be adjusted according to the site of cancer and lymph node metastasis. 
4.5.2 Postoperative chemotherapy 
After surgery, patients with the following high-risk and adverse prognostic factors should be 
supplemented with chemotherapy concurrently with radiotherapy: positive tumor margin (less than 
5 mm or tumor cells are seen on the margin); extracapsular lymph node metastasis. Of note, 
postoperative chemotherapy should not be started until camrelizumab-related toxicity is less than 
grade 2. 
4.6 Perioperative safety assessment 
From the start of treatment to the last injection of camrelizumab within 90 days, or within 30 
days after the completion of the operation, the patient’s medical records should be reviewed once a 
week to evaluate the complications of the operation, guide whether to delay the operation and assess 
potential immune-related side effects. irAE will be discussed in regular meetings held every one to 
two weeks, and the discussion time and content of the meeting will be recorded. If the subject refuses 
to continue his or her perioperative treatment due to personal reasons, every attempt will be made 
to collect this information either by direct contact or through communication with the subjects 
outside physician. 
5. Laboratory research 
5.1 Tissue specimen 
Specimens of subjects will be collected in unified standards. At least 0.5 cm3 of tissue biopsy 
should be incised to meet the requirements of frozen biopsy and other examinations. 10 mL of blood 
and 10 mL of saliva should be collected in the morning without eating. The time points of blood and 
saliva collection include: the day on each Camrelizumab injection, 3 days (+/-2 days) before surgery, 
3 days (+/-2 days) before radiotherapy, every follow-up. The surgically resected specimens should 
retain at least 1 cm3 of fresh tumor tissue and 0.5 cm3 of adjacent mucosal tissues, and cryopreserved 
in -80℃ refrigerator for subsequent research. 
5.2 Handling of biopsy specimen 
The tumor tissue biopsy specimen is divided into three pieces, one is used for frozen biopsy to 
diagnose the nature and pathological classification of the disease, one is used for 

14 
 
immunohistochemical to detect markers of cell and molecular, and the last one is stored in a liquid 
nitrogen tank for future RNA or DNA analysis. 
The tumor tissue biopsy specimen should be fixed in 10% formalin or 4% paraformaldehyde 
solution within 30 minutes after being isolated for no less than 12 hours, and the tissue should be 
embedded within 24 hours. The slice thickness is 4 μm, and at least 15 slices should be cut. The 
slice should be clearly marked with the patient's study number, date and time, and consecutive 
sample numbers. 
5.3 Handling of surgical tumor specimen 
The surgical tumor specimen should be processed within 30 minutes and be divided into two 
pieces of tissue not less than 0.5 cm*0.5 cm in size: one piece is immediately lysed into a single cell 
suspension, and stored frozen according to the corresponding experimental manual; the other part 
tissue directly frozen in liquid nitrogen tank for RNA sequencing. The remaining tissues and a part 
of the lymph nodes are embedded, sliced and labeled according to the method of fixing tissue biopsy 
specimens and sent to the tissue chip. 
5.4 Handling of blood 
Whole blood will be collected and processed per manufacturer’s instructions of PMBC. Aliquot 
the upper plasma into 500 μL/tube and store it at -80 °C for later ELISA or Western Blot analysis; 
Aliquot the middle PBMC into 500 μL/tube and freeze it in liquid nitrogen for subsequent study. 
5.5 Handling of saliva 
Saliva will be collected and centrifugated at 2,600 g, for 15 min, the supernatant will be 
centrifugated at 2,600 g for 15 min. Aliquot the supernatant into 500 μL/tube and store it in -80 °C 
nitrogen for subsequent study. 
6. Screening and discontinued /withdrawal 
This trial is open to all races and ethnicities, and this clinical trial does not discriminate against 
gender or race. 
6.1 Inclusion criteria 
1. 
Histologically documented oral squamous cell carcinoma (biopsy required). 
2. 
Local advanced oral squamous cell carcinoma (clinical stage T1-2N1-3M0, T3-
4aN0-3M0) with resection option for potential cure, as assessed by a faculty surgeon at 
Hospital of Stomatology, Wuhan University.  
3. 
Distant metastasis was excluded by chest CT and emission computed tomograph. 

15 
 
4. 
Adequate organ function as follows: 
1) 
Leukocyte count ≥ 2,000/mm3 
2) 
Absolute neutrophil count ≥ 1,000/mm3 
3) 
Platelet count ≥ 100,000/mm3 
4) 
Hemoglobin ≥ 90 g/Ld 
5) 
Serum albumin ≥ 30 g/L 
6) 
Total bilirubin ≤ 1.5 × upper limit of normal (ULN) 
7) 
AST (SGOT) and ALT (SGPT) < 2.5 × ULN 
8) 
ALP ≤ 2.5 × ULN 
9) 
Prothrombin time-international normalized ratio ≤ 1.5 
10) Serum creatinine ≤ 1.5 × ULN 
11) INR/PT≤ 1.5 
12) TSH ≤ ULN. 
5. 
ECOG performance status 0-1. 
6. 
Female patient tested HCG negative in serum or urine within 7 days prior to the start 
of investigational product. Both patient and partner must agree to use contraception prior to 
study entry and for the duration of study participation and for up to 120 days after the last dose 
of PD-1 blockade. 
Patient understands the study regimen, its requirements, risks and discomforts and is able and 
willing to sign the informed consent form. 
6.2 Exclusion Criteria 
1. 
History of ≥ 3 grade immune related adverse events (irAEs) or have not recovered 
to ≤ 1 grade irAEs from previous treatment. 
2. 
History of other treatments for cancer, including surgery, chemotherapy, 
radiotherapy or molecular targeted therapy within past 5 years. 
3. 
Previous therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 or any other 
antibody targeting T cell co-regulatory pathways. 
4. 
Active autoimmune disease or history of refractory autoimmune disease. 
5. 
Active systemic infection requiring therapy. 
6. 
Patients who are receiving psychotropic drug or alcohol/drug abuse. 
7. 
Subjects with concurrent other active malignancies. 
8. 
HIV or untreated active HBV or HCV infections, or vaccinated (HBV, flu, varicella, 
etc) within 4 weeks before recruitment. 
9. 
Uncontrollable systemic diseases, including diabetes, hypertension, etc. 
10. History of stroke or transient ischemic attack within past 6 months. 
6.3 Withdrawal from study 
1. 
The reasons for withdrawal from the study include: 
2. 
The subject withdraws the informed consent and asks to withdraw; 
3. 
Those who cannot tolerate the toxicity of TPF chemotherapy or Camrelizumab 
immunotherapy; 

16 
 
4. 
The subjects have poor compliance; 
5. 
The subject is lost to follow-up or lost contact; 
6. 
The subject has a sudden illness or other situation during the experiment, and the 
situation will greatly affect the evaluation of the clinical state or the study treatment needs to be 
stopped; 
7. 
Subjects are followed up for two years; 
8. 
The researcher believes that it is necessary to withdraw the subject from the research. 
Note: If subjects experience ultra-progressive imaging or serious immune-related adverse 
reactions after the first neoadjuvant immunotherapy, the second neoadjuvant immunotherapy should 
be stopped, and the patient's status should be adjusted directly before surgery and subsequent 
treatment. For subjects who are discontinued/withdrawn, the investigator must make every effort to 
complete the validity and safety inspections when launching the trial specified in the protocol, 
complete the safety follow-up, comprehensively record the adverse events and outcomes; complete 
the survival follow-up and record follow-up treatment plan and subject's survival status. The reason 
for treatment interruption should be carefully recorded in the medical record. Researchers can 
suggest or provide new or alternative therapies to subjects based on the patient's condition. If the 
subject interrupts or withdraws from the study, the researcher should collect blood, saliva and other 
specimens as much as possible with the consent of the subject. 
7. Study procedures 
 
7.1 Clinical operation schedule 
7.1.1 Screening stage, 1-7 days prior to enrollment 

17 
 
1. Clinical examination and taking pictures to record the lesions, the lesion should meet T1-
2N1-3M0, T3-4aN0-3M0; 
2. Systemic examination to exclude the contraindications of surgery; 
3. Take enhanced CT/MRI records of head and neck region to record the tumor status, and take 
emission computed tomography to exclude distant metastasis; 
4. Tumor biopsy; 
5. 10 ml of blood and saliva collection; 
6. Subject should sign the informed consent form, then researcher submit the basic information 
to the electronic data collection system and divide the subject into a treatment group through the 
randomization system. 
7.1.2 Neoadjuvant stage, day 1-40 (+/-7 days) after enrollment 
1. Neoadjuvant immunotherapy 
200 mg of Camrelizumab injection at the time points of day 1, day 15 and day 29. 
2. TPF induction chemotherapy 
Day 1: Deep venous catheterization (no chemotherapy drug injection on the same day, only for 
camrelizumab). 
Day 2: 
a. 5% GNS 1000 ml + 10% KCl 10 ml iv gtt (6-8 h prior to CDDP); 
b. Normal saline 50 ml + 5-HT3 receptor antagonist (such as ondansetron 8 mg or glastron 3 
mg or tropisetron 5 mg) iv gtt (30 minutes prior to chemotherapy, additional one administration is 
needed if severe nausea occurs); 
c. Dexamethasone 5 mg iv + Promethazine 25 mg im (docetaxel pretreatment); 
d. Normal saline 500 mg + docetaxel 75 mg/m2 iv gtt for 2-3 hours; 
e. Normal saline or glucose solution 500 ml + 10% KCl 10 ml + dexamethasone 5 mg iv gtt 
for 3 hours; 
f. 20% mannitol 50 ml iv (before cisplatin use); 
g. 5% glucose solution 500 ml + CDDP 75 mg/m2 iv gtt for 1-2h; 
h. 20% mannitol 50 ml iv q1h×5 times; 
i. Normal saline or glucose solution or Ringer's solution 1000 ml + 10% KCl 10 ml + 

18 
 
dexamethasone 5 mg iv gtt for 3 hours; 
j. Normal saline 500 ml + 5-FU 750mg/m2/d×5 d iv gtt; 
k. Ringer's solution 500 ml + vitamin C 2 g + vitamin B6 200 mg iv gtt; 
l. Other auxiliary drugs such as hepatinica. 
Day 3: 
a. 1500 ml normal saline or glucose solution + 10% KCl 20 ml + dexamethasone 10 mg iv gtt; 
b. 20% mannitol 50 ml iv q1h×3 times; 
c. Normal saline 50 ml + central nervous antiemetics (5-HT3 receptor antagonists, such as 
ondansetron 8 mg or granisetron 3 mg or tropisetron 5 mg) iv gtt (1-2 times a day or according to 
the severity of nausea and vomiting); 
d. Ringer's solution 500 ml + vitamin C 2 g + vitamin B6 200 mg iv gtt; 
e. Other auxiliary drugs such as hepatinica. 
Day 4-6: 
a. Normal saline 50 ml + central nervous antiemetics iv gtt; 
b. Ringer's solution 500 ml + vitamin C 2 g + vitamin B6 200 mg iv gtt; 
c. Other auxiliary drugs such as hepatinica. 
Days 7-21: Rest (the patient needs to return to the hospital for the second camrelizumab 
injection on day 15). 
Day 22-26: Repeat the content of Days 1-6 and perform a second course of TPF chemotherapy. 
Day 27-42: Rest (return to the hospital on day 29 for the 3rd camrelizumab injection) 
7.1.3 Surgery stage 
Preoperative examination, 1-3 days prior to surgery. 
1. Clinical examination and taking pictures to record the lesions; 
2. Take enhanced CT/MRI records of head and neck region to record the tumor status, and take 
emission computed tomography to exclude distant metastasis; 
3. 10 ml of blood and saliva collection; 
Surgery day 
1. Take pictures to record the operation method and the number of separated lymph nodes. 
2. Collect tumor specimen and store it as described above. 

19 
 
7.1.4 Adjuvant therapy stage, 30 days (+/-10 days) postoperation 
Prior to radiotherapy 
1. Clinical examination and enhanced CT/MRI examination. 
2. 10 ml of blood and saliva collection. 
3. Design the plan of radiotherapy according to surgical records, silver clip markers and 
pathology reports. 
4. Concurrent chemoradiotherapy: 
a. Subjects with the following high-risk and poor prognostic factors: positive resection margin 
(less than 5mm or visible tumor cells on the resection margin); extracapsular invasion of lymph 
nodes. 
b. The concurrent chemoradiotherapy plan: The subject will receive CDDP 80 mg/m2 
administration each 3-week cycle for 2 cycles.  
7.1.5 Follow-up stage 
The first follow-up will start at 90 days (+/-10 days) after the end of radiotherapy with an 
interval of 3 months (+/-10 days) for a total of 7 follow-ups. The contents of follow-up include: 
①Clinical examination. 
②10 ml of blood and saliva collection. 
③Head and neck enhanced CT/MRI examination, performed at the 1, 3, 5, and 7 visits. 
④Assessment, management and record of the irAEs, and analyze the correlation between the 
irAEs and the study drug. Once identified as irAE, it should be submitted to National Medical 
Products Administration in time. 
It is worth noting that if the patient cannot be followed up on schedule, the patient should return 
to hospital within two months, and the follow-up will continue as scheduled. If the patient cannot 
be followed up for three consecutive times, it should be considered as drop-out, and the reason for 
drop-out should be recorded. Though the data of drop-out patient cannot be used for the analysis of 
laboratory indicators for dynamic monitoring of the patient's condition, it can still be used to 
evaluate the safety and effectiveness of neoadjuvant immunotherapy. 
7.2 Specimen processing schedule 
7.2.1 Screening stage 

20 
 
①Collect the biopsy specimen and divide it into two pieces, one piece will be frozen with 
RNAlater nucleic acid preservation solution in liquid nitrogen, and the other one will be used for 
frozen biopsy and then taken out to be re-fixed with formalin and embed in paraffin; 
②Collect 10 ml blood (EDTA anticoagulation vacuum tube) and 10 ml saliva from the subject 
before eating in the morning. Whole blood will be collected and processed per manufacturer’s 
instructions of PMBC. Aliquot the upper plasma into 500 μL/tube and store it at -80 °C for later 
analysis; aliquot the middle PBMC into 500 μL/tube and freeze it in liquid nitrogen for subsequent 
study. Saliva will be collected and centrifugated at 2,600 g, for 15 min, the supernatant will be 
centrifugated at 2,600 g for 15 min. Aliquot the supernatant into 500 μL/tube and store it in -80 °C 
nitrogen for subsequent study. 
7.2.2 Surgery stage 
On the first day after admission, collect the patient's blood and saliva, the method is described 
as 7.2.1; 
On the surgery day, collect about 1×1×1 cm3 of the most representative tumor and divide it into 
3 pieces. One piece is prepared for single cell suspension following the, then frozen in a liquid 
nitrogen tank, and one piece is fixed with formalin, embedded in paraffin, add a piece of RNAlater 
nucleic acid preservation solution and freeze it in a liquid nitrogen tank. 
7.2.3 Adjuvant chemoradiotherapy stage 
On the first day after admission, collect the patient's blood and saliva, the method is described 
as 7.2.1. 
7.2.4 Follow-up stage 
After adjuvant radiotherapy, patients will have regular follow-up visits every 3 months for a 
total of 7 visits for two years. Blood and saliva will be collected every time, the method is described 
as above as 7.2.1, but fasting collection is not required. 
8. Study drug 
8.1 Drug description 
Camrelizumab will be ordered from Hengrui Pharmaceutical Co., Ltd. Each bottle of 200mg 
can only be used once. The drug label is shown in Table 1. 
 

21 
 
Table 1 
Product description 
Specifications 
Size 
Appearance 
Storage 
Lyophilized powder of 
camrelizumab 
200 mg 
20mL 
injection bottle 
Transparent glass 
bottle, white powder 
2-8 ℃, keep away from 
light and freezing 
8.2 Pharmacokinetics of camrelizumab 
A phase I study evaluated the pharmacokinetics of camrelizumab in 49 patients with advanced 
solid tumors in China at different doses (1 mg/kg, 3 mg/kg, 10 mg/kg and 200 mg/time). The study 
showed that the in vivo exposure (Cmax) of camrelizumab increased with the increase of dosage in 
the range of 1-10 mg/kg after a single administration. After multiple administration (once every 2 
weeks), the average steady-state accumulation ratio calculated according to Cmax on the 15th day 
of the fourth cycle is between 1.11-1.35. 
8.3 Safety summary and side effects of camrelizumab 
The comprehensive treatment measures of potential camrelizumab related toxic and side 
effects are recorded in detail in the annex and the researcher's manual. Combined with previous 
clinical trials, more than 10% of the side effects were mainly reactive capillary hemangioma (79.3%), 
anemia, fever, fatigue, hypothyroidism, proteinuria and cough; 1% - 10% of side effects include 
anemia, hypernatremia, lung infection, elevated aspartate aminotransferase level, elevated 
glutamyltransferase level, elevated blood bilirubin level, elevated bilirubin level, abnormal liver 
function, decreased neutrophil count, decreased leukocyte count, thrombocytopenia, decreased 
lymphocyte count, hypokalemia, increased alanine aminotransferase level, pneumonia, increased 
blood alkaline phosphatase level and increased lipase level. 
8.4 Disposal and distribution of camrelizumab 
Camrelizumab is managed by a specially assigned person set up by the main investigator of 
the clinical trial and stored in a separate refrigerator for the clinical trial. The drug administrator 
shall ensure that the drug is stored in a suitable environment (temperature, light, humidity). If there 
is any doubt about the quality and appearance of the drug, the supply company should be contacted 
directly. The bottles of camrelizumab should be stored in a refrigerator at 2-8 ℃ away from light 
and avoid freezing. If it is stored in a glass cabinet refrigerator, it should be stored in the packing 
box. It is recommended to wear work clothes and gloves when transporting or preparing drugs. 

22 
 
When distributing drugs, the drug receiving form shall be signed by two persons in duplicate. 
The clinical research unit and the application department shall supervise the supply, use and storage 
of drugs and the treatment process of remaining drugs. 
8.5 Injection method of camrelizumab 
The patients in the test group will be injected with carrelizumab once on day 1, day 15 and day 
29, with 200 mg each time. Dilute the drug into 100 ml glucose or sodium chloride injection. 
Infusion should be completed within 30-60 minutes. 
Camrelizumab does not contain preservatives, so aseptic operation is needed. Each bottle of 
camrelizumab for injection should be re dissolved with 5 ml of sterile water for injection. Avoid 
directly spraying the water droplets on the surface of the powder, and slowly add it along the bottle 
wall, slowly swirl it to dissolve, and put it to the foam to dissipate, and do not shake violently. The 
solution shall be colorless or yellowish liquid. If visible particles are observed, stop the injection 
and replace the drug. Transfer 5 ml of the solution to the infusion bag containing 100 ml of glucose 
injection (5%) or sodium chloride injection (0.9%), and conduct intravenous infusion through a 
sterile, pyrogen free and low protein binding 0.2 µM filter. 
Camrelizumab should be dissolved and diluted immediately after removal from the refrigerator. 
Store the diluted solution at room temperature for no more than 6 hours 
(including infusion time): store it under refrigeration (2-8 ℃) for no more than 24 hours. If 
the diluted solution is stored under refrigeration, it should be restored to room temperature before 
use. Note that this drug should not be administered simultaneously with other drugs. 
8.6 Destruction of research drugs 
The investigator shall ensure that the drug is destroyed and archived in accordance with 
relevant regulations, guidelines, systems and procedures. 
9. Safety evaluation 
9.1 Safety summary 
This study will use the description and grading scale of adverse event reports in the revised 
National Cancer Institute Common Terminology Standard for adverse events (CTCAE) version 5.0. 
Information on all adverse events, whether voluntarily provided by the subject, found through the 
inquiry of the investigator, or detected through physical examination, laboratory test or other means, 

23 
 
will be collected, recorded and tracked. 
All adverse events experienced by subjects will be collected from the first medication, 
throughout the whole study process, and at least 90 days after the last treatment. Subjects who still 
have toxic and side effects after discontinuing the study drug should be further evaluated and 
followed up until the toxic and side effects disappear or are determined to be irreversible. Any 
preoperative and postoperative adverse events should be carefully recorded. 
9.2 Adverse event 
9.2.1 Definition of adverse events 
Adverse event refers to any new unpleasant medical event or deterioration of previous 
symptoms during the use of the drug by the patient or subject, and the drug does not necessarily 
have a causal relationship with the treatment. Therefore, adverse events can be any adverse and 
unexpected manifestations (including abnormal laboratory results), symptoms or diseases 
temporarily related to the study drug. 
Adverse events can be reported or described in the process of open inquiry, examination or 
evaluation at the same time. To prevent reporting bias, subjects should not ask about the specific 
circumstances of one or more adverse events. The medical condition / disease occurring before the 
start of the study treatment is considered an adverse event only when the condition worsens after 
the start of the study treatment (any step in the treatment procedure). Although it happened before 
treatment, the adverse events after signing the informed consent should also be recorded. Abnormal 
laboratory results or adverse events caused by them constitute adverse events only when they cause 
clinical symptoms or need treatment. 
9.2.2 Serious adverse events (SAE) 
① Serious adverse events refer to the following adverse clinical consequences: 
a) Death (excluding death caused by tumor recurrence or metastasis); 
b) Life-threatening (it means that the subject is in danger of life, not that it will be life-
threatening if it worsens further); 
c) Need to be hospitalized or extended; 
d) Cause persistent or significant disability or dysfunction; 
e) Important clinical events (Although it will not immediately endanger life, cause death or 

24 
 
cause hospitalization, according to reasonable clinical diagnosis, the event will endanger the 
subject's life or require intervention, otherwise the consequences listed above will occur. These 
events include, but are not limited to, intensive treatment for allergic bronchospasm in the 
emergency or at home, vasospasm or convulsion without hospitalization. Potential drug-induced 
liver injury is also listed as a serious medical event) 
② The following hospitalizations are not serious adverse events: 
a) Not more than 24 hours in emergency or other medical departments, except for "important 
medical events" or life-threatening events; 
b) Scheduled surgery before signing informed consent; 
c) Treatment or surgery according to the trial process; 
d) Routine medical examination (such as routine colonoscopy); 
e) Admission treatment planned before enrollment, but its purpose is not to treat diseases; 
f) The subjects were hospitalized due to the impact of their personal living environment 
(inability to housing, lack of economic capacity, etc.). 
9.2.3 Unexpected adverse events 
Any adverse events not covered in the informed consent form are unexpected adverse events. 
9.2.4 Expected adverse events 
The adverse events involved in the investigator's manual and informed consent documents are 
considered as expected adverse events. 
9.3 Sorting and reporting of serious adverse events 
After the subject signs the informed consent to participate in the clinical trial study, whether it 
is related to the study drug or not, all serious adverse events should be sorted and collected, including 
those that may be related to the treatment procedure. 
Within 24 hours after the occurrence of serious adverse events, the researcher shall report to 
the ethics committee, the provincial drug administration, Safety Supervision Department and 
Registration Department of the State Drug Administration and the local health administrative 
department in time. All reports shall have written materials for inspection and verification, and shall 
be archived as test data. 
9.4 Non-serious adverse events 

25 
 
Non-serious adverse events refer to the types of adverse events that do not belong to serious 
adverse events. 
All non-serious adverse events should be recorded during treatment and at least 90 days after 
the last injection treatment. Non-serious adverse events should be tracked to whether they are 
resolved and whether the symptoms persist or turn into serious adverse events. Non-serious adverse 
events leading to the interruption or withdrawal of study drugs or adverse events at the end of 
treatment also need to be followed up as appropriate. All non-serious adverse events need to be 
carefully recorded in the paper or electronic medical record system. 
9.5 Abnormal laboratory test results 
For adverse events and laboratory abnormalities found during the study, the case report form 
should be improved. Serious adverse event case report (paper or electronic) shall be reported as 
appropriate. 
a) Laboratory test results of any serious or serious adverse events; 
b) Any abnormal index of laboratory results requiring drug withdrawal; 
c) Any abnormal index of laboratory results requiring special treatment; 
Researchers should try to use clinical terms rather than laboratory terms, such as anemia and 
low hemoglobin. 
9.6 Gestation 
If the subject finds pregnancy after the start of the study, including within six half-lives after 
drug injection, the subject will permanently stop the clinical trial. Unless pregnancy is 
contraindicated, the subject must undergo the prescribed study suspension and follow-up procedures. 
If necessary, other appropriate pregnancy follow-up procedures should be considered. The 
researcher should report to the ethics committee of School and Hospital of Stomatology Wuhan 
University and Hubei Food and Drug Administration within 24 hours. 
Follow up information on the pregnancy process, including perinatal and neonatal outcomes, 
must be reported on the pregnancy monitoring form. Any pregnancy that occurred in a female 
partner of a male subject should also be reported to the investigator. The information about this 
pregnancy should be reported to the ethics committee of School and Hospital of Stomatology Wuhan 
University. 

26 
 
9.7 Overuse 
Overuse refers to conscious or unconscious overuse. All overuse should be reported as serious 
adverse events. 
9.8 Other safety precautions 
The deterioration found in the mid-term or final physical examination, ECG, X-ray 
examination and other potential risk assessment (whether it belongs to the examination in the test 
process or not) shall be recorded as non-serious or serious adverse events and reported as appropriate. 
10. Effectiveness evaluation 
The objective remission rate (imaging and pathological remission rate), recurrence rate, 
progression free survival rate, one-year survival rate and overall survival rate were evaluated. 
In this clinical trial, all subjects underwent imaging examination at baseline, before operation 
and every two months after operation, and all subjects underwent pathological biopsy and surgical 
pathological biopsy. The clinical tumor imaging evaluation was carried out through the solid tumor 
efficacy evaluation standard version 1.1 (see the research manual), and the pathological grading was 
carried out by hematoxylin eosin staining of pathological sections. 
All patients' imaging examinations (enhanced CT or MRI) were confirmed by independent 
imaging experts in a blind manner. All subjects with curative effect evaluation of CR, PR, SD and 
PD shall be reviewed by the person in charge first, and the imaging data of all curative effect 
evaluation (image film or image examination CD) shall be retained, and finally evaluated and 
confirmed by independent imaging experts. Similarly, the pathological examination of all patients 
is confirmed by independent pathologists in a blind manner. For the subjects evaluated as 
pathological complete remission (pCR), pathological partial remission (pPR) and non-pathological 
remission (Non-resp), the person in charge shall review and retain all evaluated pathological data 
(microscope photos or pathological sections). Finally, they should be evaluated and confirmed by 
independent pathological experts. The exploratory research on the tissue, blood and saliva samples 
will be carried out by the laboratory personnel in a blind state, and the blindness will be uncovered 
after the experimental data are obtained. 
11.Exploratory study 
11.1 Tissue and body fluid analysis 

27 
 
Tumor cells, infiltrating lymphocytes, and other cells in the tumor microenvironment (such as 
tumor-associated fibroblasts, lymphatic endothelial cells, vascular endothelial cells, and vascular 
endothelial cells) and their surface molecular changes were compared before and after treatment 
using immunohistochemistry, flow cytometry, and other methods. 
Tumor samples were sequenced for DNA or RNA before and after therapy to assess tumor 
mutational burden (TMB), microsatellite instability (MSI), and mismatch repair (MMR). 
Flow cytometry, ELISA, Western blotting, and other techniques were used to assess 
extracellular vesicles (EVs), lymphocytes, and the molecules they contain in blood and saliva, as 
well as to dynamically monitor the changes at various treatment phases. 
11.2 Screening of immune response markers for anti-PD-1 therapy 
The researchers looked at the associations between the patients' baseline markers, especially 
the PD-L1 composite positive score (PD-L1 CPS), MSI, MMR, and EVs subgroup molecules, and 
the efficacy of neoadjuvant treatment. 
The changes of each indicator before and after treatment were studied, as well as the 
relationship between them and the efficacy of neoadjuvant therapy and the patients' prognosis. 
Screen the indicators with clear clinical significance and possible biomarkers from the above 
data, and evaluate their sensitivity and specificity as tumor diagnostic markers or treatment 
effectiveness markers, as well as their practicality as biomarkers for predicting immunotherapy 
efficacy. 
11.3 Indicators to be detected 
This study's preliminary design includes the detection of tumor cells, immune cells, monocytes, 
extracellular vesicles, and their subgroups. 
Tissue biopsies and surgically resected specimens, as well as drainage fluids, blood, and saliva 
from patients with oral squamous cell carcinoma, will be analyzed for immune response markers.All 
samples were analyzed using multicolor flow cytometry, immunohistochemistry and in situ 
hybridization techniques to look for candidate immune response markers related to anti-PD-1 
therapy, including expression in peripheral blood lymphocytes, tumor-infiltrating lymphocytes, 
lymph nodes, and tumor cells. 
 

28 
 
Table 2 Protein molecular detection 
Molecular 
Molecular function 
CD4, CD8 
Involved in the interaction of T cell receptors with antigen presenting cells 
CD25 
IL-2 receptor, involved in suppressing antitumor immunity 
HLA-DR 
Expression of immune recognition antigens 
CD45RO 
Enhance anti-tumor immunity 
FoxP3 
It plays an important role in the formation of regulatory T cells and participates in the 
inhibition of anti-tumor immunity 
LAP 
Potential markers of activated regulatory T cells 
PD-1/PD-L1 
Inhibition of anti-tumor immunity, PD-1 is the therapeutic target of camrelizumab 
LAG-3 
Collaborate PD-1 suppresses anti-tumor immunity 
ICOS 
Stimulates T cells to act on tumor cells 
CTLA-4 
Immune checkpoint molecules that suppress antitumor responses 
12. Management of adverse events 
12.1 Infusion reaction 
There have been reports of camrelizumab infusion reaction during injection, and clinical 
symptoms and signs should be closely monitored following treatment. Fever, chills, stiffness, 
headache, rash, pruritus, Alsace illness, hypotension, hypertension, bronchospasm, or other allergic-
like events might happen as a result of infusion reactions. For patients with Grade 1 infusion 
reactions, therapy can be continued under close monitoring; If an infusion reaction of grade 2 occurs, 
the infusion rate can be slowed or the infusion can be stopped. Antipyretic and analgesic anti-
inflammatory drugs, and also antihistamines, may be recommended. When the symptoms have 
subsided, the medicine can be restarted but must be closely monitored. Grade 3 or higher infusion 
responses must be stopped instantly and reported as serious adverse events (SAEs). Infusion 
reactions were graded according to the NCI CTCAE (version 5.0) guidelines. Recommendations for 
the treatment of infusion reactions are as follows: 
Grade 1 infusion reaction：A mild reaction that does not need stopping the infusion. Keep an 
eye on things until the symptoms disappear. In the future, 30 minutes before re-dosing, take 50 mg 
diphenhydramine and（or） paracetamol/acetaminophen 325-1000 mg orally.  
Grade 2 infusion reaction: A moderate reaction that necessitates treatment or suspension of 
infusion, and requires symptomatic medication, such as antihistamines, nonsteroidal anti-

29 
 
inflammatory drugs, anesthetics, corticosteroids, intravenous infusion, and so on; preventive 
medication can be given up to 24 hours in advance. Stop the camrelizumab injection and replace it 
with intravenous saline, intravenous diphenhydramine 50 mg, or paracetamol/acetaminophen 325-
1000 mg; monitor the patient attentively until the symptoms disappear. Corticosteroid treatment can 
also be applied in the proper situations. If the symptoms disappear， the injection can be resumed 
at half the initial rate of infusion. If no symptoms appear 30 minutes after the re-injection, the 
injection can be continued at the original infusion rate, although close monitoring is still necessary. 
If the infusion reaction occurs again, no further infusion treatments will be administered. In the 
future, 
30 
minutes 
before 
re-dosing, 
take 
50 
mg 
diphenhydramine 
and/or 
paracetamol/acetaminophen 325-1000 mg orally. Corticosteroid treatment can also be utilized as 
necessary.  
Grade 3 or 4 Infusion reactions：Serious infusion reactions, Grade 3 reactions: symptoms that 
do not improve after long-term symptomatic treatment or infusion suspension; initial infusion 
reactions that reappear with the second infusion; other severe symptoms that require hospitalization 
[such as kidney damage, pulmonary infiltration]. 
12.2 Immune-related adverse events 
Immune-related adverse events can occur during and after immunotherapy is ended, and then 
they can affect any tissue or organ and, in severe cases, result in the patient's death. Suspected 
immune-related adverse events should be fully examined to rule out other possible causes. The 
majority of immune-related adverse events were reversible and may be handled with drug 
discontinuation, corticosteroid injections, or supportive care. Most grade 2 and some specific grade 
3 or 4 immune-related adverse events need drug discontinuation during therapy, and some grade 3 
and 4 immune-related adverse events require permanent stop. Furthermore, if any recurring grade 3 
immune-related adverse events after therapy, grade 2 or 3 immune-related adverse events that did 
not improve to grade 0-1 within 12 weeks from the last dose, the corticosteroid cannot be reduced 
to a 10 mg/day equivalent dose of prednisone within 12 weeks of the last dose, the drug should be 
stopped permanently. The descriptions here are based on the first version of the NCCN Guidelines 
for the Management of Immunotherapy-Related Toxicity, published in 2019. (Refer to the Research 
Manual for details). 

30 
 
12.2.1 Immune-Related Skin Adverse Events 
Immune-related cutaneous adverse events occurred in 2.8% of camrelizumab patients, with 
1.3 % having grade 1, 0.8% having grade 2, and 0.7% having grade 3. For grade 1 or 2 rash, 
symptomatic therapy or topical corticosteroids can be given. Camrelizumab treatment should be 
stopped, and symptomatic treatment or topical corticosteroids should be offered in the case of a 
grade 3 rash. If a grade 4 rash, Scottish-Johnson syndrome, or toxic epidermal necrolysis occurs, 
camrelizumab treatment should be discontinued completely. 
12.2.2 Immune-related gastrointestinal adverse events 
In previous treatment, the incidence of immune-related gastrointestinal adverse events was 
0.9%, of which 0.7% had immune-related diarrhea, all grade 3, 0.1% had grade 3 colitis, and 0.1% 
had grade 5 colitis. Patients should be followed for signs and symptoms associated with immune-
related gastrointestinal adverse events, such as stomach ache, diarrhea, mucus or bloody stools, and 
infection and disease-related causes should be eliminated in the case of immune-related 
gastrointestinal adverse events. Camrelizumab therapy should be deferred for grade 2 or 3 immune-
related diarrhea or colitis, and should be completely discontinued for grade 4 or recurring grade 3 
immune-related gastrointestinal adverse events. At the same time, the potential risk of intestinal 
perforation should be considered and confirmed by imaging and/or endoscopy if necessary. 
12.2.3 Immune-related hepatic adverse events 
On prior therapy, the incidence of immune-related hepatic adverse events was 9.1%, including 
0.1% for grade 2, 7.0% for grade 3, 1.5% for grade 4, and 0.5% for grade 5. Changes in liver function 
and the related symptoms and signs of hepatitis should be followed once a month during regular 
treatment of patients, and infections and underlying disorders should be eliminated. If immune-
related hepatic adverse events occur, liver function tests should be performed more often. 
Camrelizumab treatment should be discontinued for grade 2 immune-related hepatic adverse 
events.  If there are grade 3 or 4 immune-related hepatic adverse events, camrelizumab treatment 
should be stopped completely. 
12.2.4 Immune-related pancreatic adverse events 
There were no immune-related pancreatic adverse events in prior therapy. The incidence of 
immune-related amylase or lipase increase was 1.3%. Lipase increase was 1.0%, with grade 3 at 

31 
 
0.6% and grade 4 at 0.4%. The amylase increase was 0.3%, all of which were grade 3. 
12.2.5 Immune-related endocrine adverse events 
①High blood sugar 
On prior treatment, the incidence of elevated blood glucose was 1.5%, 0.8% for grade 1, 0.6% 
for grade 3, and 0.1% for grade 4. The incidence of diabetes was 0.2%, all of which were grade 3. 
Patients' blood glucose levels, as well as any related clinical signs and symptoms, should be closely 
monitored. Camrelizumab treatment should be deferred in type 1 diabetes patients with poor 
glycemic control, and insulin replacement therapy should be halted until symptoms disappear. 
Camrelizumab must be permanently stopped in patients with life-threatening grade 4 type 1 diabetes. 
Blood glucose levels should be evaluated in the future to ensure that insulin replacement treatment 
is effective. 
②Thyroid changes 
In previous treatment, the incidence of hypothyroidism was 20.5%, including 12.8% for grade 
1 and 7.7% for grade 2; the incidence of hyperthyroidism was 6.7%, of which 5.7% for grade 1 and 
1.0% for grade 2; The incidence of thyroiditis was 0.3%, with 0.2% for grade 1 and 0.1% for grade 
2. Patients should be closely monitored for changes in thyroid function and corresponding clinical 
symptoms and signs. For symptomatic grade 2-3 hypothyroidism, camrelizumab therapy should be 
withheld and thyroid hormone replacement therapy initiated as needed. Camrelizumab should be 
discontinued in patients with symptomatic grade 2-3 hyperthyroidism, and antithyroid medications 
should be used as needed. Camrelizumab withholding and hormonal treatment may be explored if 
acute thyroid inflammation is suspected. Camrelizumab treatment can be continued if symptoms of 
hypothyroidism or hyperthyroidism improve and thyroid function tests return to normal.  If you 
have life-threatening hyperthyroidism or hypothyroidism, Camrelizumab should be stopped 
completely. Thyroid function should be evaluated in the future to ensure that hormone replacement 
treatment is effective. 
③Adrenal gland changes 
Adrenal insufficiency occurred in 0.4% of patients with previous treatment, with grade 1 in 
0.1%, grade 2 in 0.2%, and grade 3 in 0.1%. Adrenal insufficiency symptoms should be closely 
monitored in patients. Camrelizumab treatment should be discontinued for symptomatic grade 2 

32 
 
adrenal insufficiency, and physiologic corticosteroid replacement therapy should be administered as 
clinically necessary until symptoms disappear. Camrelizumab must be stopped completely if 
patients have Grade 3-4 adrenal insufficiency. Adrenal function and hormone levels should be 
monitored continuously to ensure proper corticosteroid replacement treatment. 
④Changes in the central system 
Hypophysitis occurred in 0.1% of previous treatments and was grade 1. Patients with 
hypophysitis should be closely monitored for signs and symptoms (including hypopituitarism and 
secondary adrenal insufficiency) and other etiologies should be excluded.  Camrelizumab should 
be withheld for symptomatic grade 2-3 hypophysitis, and hormone replacement treatment should be 
given as clinically necessary. Corticosteroids can be administered if acute hypophysitis is suspected. 
For life-threatening grade 4 hypophysitis, camrelizumab must be permanently discontinued. 
Adrenal function and corticosteroid levels should continue to be monitored to ensure appropriate 
corticosteroid replacement therapy. 
12.2.6 Immune-related pulmonary adverse events 
On prior treatment, the incidence of immune-related pulmonary adverse events was 2.7%, 
including 0.1% for grade 1, 0.9% for grade 2, 1.0% for grade 3, 0.3% for grade 4, and 0.4% for 
grade 5. Clinical symptoms and signs should be monitored during the treatment process, and 
suspected immune-related pneumonia cases should be confirmed by imaging examinations, with 
other causes being excluded out. If grade 2 immune-related pneumonitis develops, the drug should 
be stopped immediately, and if grade 3 or higher or recurring grade 2 immune-related pneumonitis 
occurs, the drug should be stopped permanently. 
12.2.7 Immune-related adverse renal events 
On prior therapy, the incidence of immune-related renal adverse events was 0.4%, including 
0.1% for grade 2 and 0.3% for grade 3. Changes in renal function, as well as accompanying 
symptoms and indicators of nephritis, should be examined on a monthly basis during therapy. If 
immune-related nephritis develops, renal function tests should be performed more often. The vast 
majority of patients with high serum creatinine are asymptomatic. Other possible causes of renal 
impairment should be ruled out. Camrelizumab should be stopped if serum creatinine levels increase 
to a level of 2 or 3. A grade 4 serum creatinine increase should permanently discontinue 

33 
 
camrelizumab therapy. 
12.2.8 Immune-related hepatic adverse events 
On prior therapy, the incidence of immune-related hepatic adverse events was 9.1%, including 
0.1% for grade 2, 7.0% for grade 3, 1.5% for grade 4, and 0.5% for grade 5. During the treatment, 
the changes of liver function and the corresponding symptoms and signs of hepatitis should be 
monitored every month, and infection and the cause related to the underlying disease should be 
excluded. If immune-related hepatitis develops, liver function tests should be performed more often. 
Camrelizumab treatment should be avoided in patients with grade 2 immune-related hepatitis. For 
grade 3 or 4 immune-related hepatitis, camrelizumab treatment should be permanently discontinued. 
12.2.9 Immune-related adverse cardiovascular events 
Immune-related platelet count reductions occurred in 1.7% of patients with prior therapy, 
including 1.2% for grade 3 and 0.5% for grade 4. Patients should be closely monitored for platelet 
levels and signs and symptoms of bleeding tendencies, and other causes of thrombocytopenia should 
be ruled out. When grade 3 thrombocytopenia occurs, camrelizumab treatment should be 
suspended , and supportive care should be given until the patient recovers to grade 0-1. 
Corticosteroid therapy should be administered based on clinical assessment and whether or not 
camrelizumab treatment may be begun. In the event of grade 4 thrombocytopenia, the drug should 
be permanently discontinued and symptomatic treatment should be taken actively, and 
corticosteroid therapy should be given if necessary. 
The incidence of immune-related myocarditis was 0.3%, with grade 1 being 0.2% and grade 5 
being 0.1%. Clinical signs and symptoms of myocarditis should be followed, and if immune-related 
myocarditis is suspected, an appropriate examination should be performed to confirm the etiology 
and rule out other possibilities, as well as necessary tests such as myocardial enzymes. 
Camrelizumab treatment should be stopped if grade 2 myocarditis occurs, and corticosteroid therapy 
should be started. The safety of continuing camrelizumab treatment after myocarditis has recovered 
to grade 0-1 is unknown. Patients with grade 3 or 4 myocarditis should be treated with corticosteroid 
medication for the rest of their lives, and their myocardial enzymes and cardiac function should be 
closely monitored. 
12.2.10 Other immune-related adverse events 

34 
 
In the previous treatment, immune-related myositis (0.2%) and conjunctivitis (0.3%) also 
occurred. For other suspected immune-related adverse reactions, adequate evaluation should be 
performed to confirm the etiology and exclude other etiologies. Depending on the severity of the 
adverse events, camrelizumab treatment should be withheld for the first occurrence of a grade 2 or 
3 immune-related adverse events. Camrelizumab treatment must be permanently discontinued for 
any recurrent grade 3 immune-related adverse reaction (excluding endocrine disease) and any grade 
4 immune-related adverse reaction. Corticosteroids should be used only when clinically needed. 
13. Research Management 
13.1 Amendments to the Scheme 
The "Clinical Research Protocol", "Clinical Research Case Report Form" and "Investigator's 
Manual" are formulated by the principal investigator, and the principal investigator and all 
investigators discuss and formulate the clinical research plan. Any changes to the trial protocol were 
approved by the Institutional Review Board in the form of an amended protocol. The principal 
investigator will be responsible for the coordination and development of clinical trial protocol 
modifications. 
13.2 Informed Consent 
The investigator will explain to each subject the nature, purpose, procedures involved, expected 
duration, potential risks and benefits of the study. Each subject will be informed that participation 
in the study is voluntary, that personal data in the trial will be kept confidential, that he/she can 
withdraw from the study at any time, and that withdrawal of consent will not affect his/her 
subsequent treatment. Informed consent will be in the form of a standard written statement and 
submitted to the Institutional Review Board for approval prior to use. Only after signing the 
informed consent form can they be enrolled in the study. According to "Good Clinical Practice for 
Drugs", the contents of the signed informed consent form include the consent to authorize the 
subject's information to the relevant research institutions, including research sponsors, research 
institutions, regulatory agencies or ethics committees, and the subject's information Include all 
hospital admissions and medical history of the subject. 
13.3 Code of Ethics and Practice for the Management of Drug Clinical Trials 
Clinical trial research shall comply with the management standards for drug clinical trials, and 

35 
 
follow the following contents: 
a) "Good Clinical Practice for Drugs" promulgated by China Food and Drug Administration; 
b) "Management Measures for Clinical Trial Projects of Wuhan University Stomatological 
Hospital; 
c) The International Ethical Guidelines for Human Biomedical Research issued by the 
International Committee of the Organization of Medical Sciences; 
d) Declaration of Helsinki. 
13.4 Regulatory authorities 
This clinical trial was supervised by the Ethics Committee of Wuhan University Stomatological 
Hospital, the Clinical Research Center of Wuhan University Stomatological Hospital and the 
National Medical Products Administration (NMPA). 
13.5 Principal Investigator (PI) Responsibilities 
The principal investigator in charge of a clinical trial should be a clinical expert in the relevant 
specialty of the drug research, who must have the knowledge of the specialty and have extensive 
clinical experience in the specialty to deal with the medical problems that may occur in the subjects. 
The principal investigator is mainly responsible for the following tasks: 
a) coordination, development, submission and acquisition of treatment protocols, and approval 
of subsequent amendments thereto; 
b) Prepare the investigator's manual, develop standard operating procedures, and design case 
report forms; 
c) ensure the use of the correct version scheme; 
d) be responsible for the overall work of this research and supervise the progress of the research; 
e) review and reporting of serious adverse events; 
f) Review data of all departments, test data processing and statistics; 
g) Assist in the writing of test reports. 
14. Data Management and Security Controls 
This clinical trial uses an electronic data capture system (EDC) to fill in an electronic case 
report form (eCRF). 
14.1 Data collection 

36 
 
Researchers can only log on to the EDC system after they have been trained. The principal 
investigator (PI) or data entry staff (CRC) entered the data into the EDC system according to the 
eCRF filling guidelines. PI or CRC are allowed to revise the data in question, but the revision date, 
the signature of the reviser, and necessary explanations must be recorded truthfully, but the original 
records cannot be covered up. 
After the database is locked, the investigator will receive a CD-ROM or file copy of the subject 
data. The original eCRF is preserved by Wuhan University Stomatological Hospital and is not 
allowed to be provided in any form except for representatives authorized by the state. 
14.2 Data curation 
The completed medical records and related research documents will be submitted to the 
research center for centralized review and data collation. The time and content of data submission 
are as follows: 
When each subject participates in clinical trial registration: 
a) Registration form 
b) Signed informed consent 
c) Eligibility Checklist 
d) Source documentation related to eligibility and randomization 
Within two weeks after registration is complete: 
a) Baseline Study Case Report Form 
b) Relevant source files 
Within two weeks after preoperative adjuvant chemotherapy: 
a) Study Case Report Form 
b) Relevant source files 
Investigators will be monitored, audited, and inspected by clinical trial-related bodies, 
including ethics committees, government regulators, and university quality management teams. 
Researchers should ensure that they have equipment capabilities for clinical trial research (eg 
pharmacy, laboratory, etc.). 
14.3 Discussion Meetings 
The study session will officially start once a subject has been enrolled. Study team members 

37 
 
participating in the trial included: study coordinators, data managers, study nurses, investigators, 
collaborators, and statisticians. 
Key topics discussed at the meeting included: relative to expected enrollment rates, subject 
characteristics, subject compliance, data validity and completeness, toxicities, procedures for 
collecting blood samples and transferring to the laboratory and further research. 
14.4 Quality Control 
In order to ensure the quality of clinical trials, before the start of clinical trials, the Clinical 
Research Center of Wuhan University Stomatological Hospital and PI jointly discuss and formulate 
clinical research plans. Provide protocol training to all relevant investigators participating in clinical 
trials. 
The PI requests Hengrui Medicine to arrange a clinical monitor. Clinical supervisors must 
follow the Good Clinical Practice (GCP) and standard operating procedures, conduct clinical 
supervision of research units on a regular basis or according to the actual situation, supervise the 
progress and progress of clinical trials, and check and confirm the records and reports of all data , 
The eCRF is filled in correctly and completely to ensure that the clinical trial is carried out in 
accordance with the clinical trial protocol, and the investigator should actively cooperate with the 
clinical supervisor. The clinical monitor or data manager will challenge the data in question to the 
PI or CRC in the form of an electronic challenge form, and the PI or CRC must respond to the 
challenge and make corrections or interpretations of the data in question, if necessary Questions are 
issued several times until the problem data is resolved. Medical leaders and data managers regularly 
perform consistent comparisons of SAEs. 
At the end of the trial project, data managers and medical staff will conduct final quality control 
of all data in the database, summarize all protocol deviations and protocol violation events during 
the trial, and hold a data verification meeting. After the data in the database meets the quality 
requirements, the database will be locked and the test will be unblinded, and the data managers will 
export the data for data analysis by the statistical department. 
15. Statistical analysis plan 
15.1 Study design 
It is estimated that the pCR rate of Camrelizumab for oral squamous cell carcinoma is 20%. 

38 
 
The pCR rate is expected to be 70% in the Camrelizumab plus TPF induction chemotherapy 
group. 
Based on no statistical hypothesis and accuracy controlling, the sample size is described as 
follows. 
The study is an exploratory research with two parallel groups with 1:1 randomization and no 
formal statistical assumptions. 
The pCR rate of the Camrelizumab group is expected to be 20%. In order to ensure that the 
lower limit of the 90% confidence interval for the observed pCR is not less than 10%, at least 27 
subjects need to be enrolled. Considering 20% dropout, the required sample size is 34 cases. It is 
estimated that the pCR rate of the Camrelizumab combined with TPF induction chemotherapy group 
is 70%. The lower limit of the 90% confidence interval of the observed pCR can be guaranteed not 
to be lower than 50% if 27 subjects enrolled in the group. Considering 20% dropout, the required 
sample size is 34 cases. In summary, the required total sample size is 68 cases. 
15.2 Data Analysis Plan 
15.2.1 Analysis of the basic characteristics of patients with locally advanced oral 
squamous cell carcinoma 
The main statistics were the mean, standard deviation, median, maximum value, minimum 
value, gender, smoking, drinking, betel nut chewing and other data of the subjects' age, height, 
weight and other data, and the confidence interval. 
15.2.2 Biosafety analysis of camrelizumab for preoperative treatment of advanced oral 
squamous cell carcinoma 
Biosafety mainly analyzes the following indicators: 
- Drug-related adverse events occurring within 90 days or 30 days (or longer) after the last dose 
of camrelizumab; 
- Drug-related serious adverse events that occurred within 90 days or 30 days (or longer) after 
the last dose of camrelizumab; 
- The most serious side effects in the laboratory results. 
15.2.3 The efficacy of camrelizumab for preoperative treatment of advanced oral 
squamous cell carcinoma: 

39 
 
Pearson correlation coefficient was used to analyze the objective response rate (imaging, 
pathological response rate), recurrence rate, etc. and 95% confidence interval; progression-free 
survival rate, one-year survival rate, overall survival rate, median survival time and its 96% 
Confidence intervals were analyzed by Kaplan-Meier. Survival data were analyzed using Kaplan-
Meier survival curves, Log-rank test and Cox proportional hazards model. Results of Cox 
proportional hazards model were reported as hazard ratios (HRs) with 95% confidence intervals 
(CIs). Descriptive analysis was used for other secondary indicators. 
15.2.4 Exploratory Immune-Efficacy Correlation Analysis 
For normally distributed data, Student's t-test and paired t-test were used for unpaired and 
paired data analysis, respectively. For normally distributed data, unpaired and paired analyses were 
performed using the nonparametric Mann-Whitney or Wilcoxon signed rank test. The correlation 
between continuous variables was analyzed by the Pearson correlation coefficient. Fisher's exact 
test was used to test the correlation between two categorical variables. 
16. Prospective research plan 
March 2021 to October 2022 
Complete subject recruitment, formulate and complete all treatment plans, record subject 
information, adverse events, collect patient tissue, blood, and saliva samples, and follow up during 
the same period. 
October 2022 to June 2023 
Complete the follow-up of all subjects, record adverse events, disease outcomes, etc., collect 
blood and saliva samples from patients during the follow-up period, and complete laboratory 
research. 
June 2023 to October 2023 
Complete data sorting and analysis, and complete thesis writing and submission. 
 
 
 
 
 
 

40 
 
17. Informed consent 
Clinical trial name: Neoadjuvant PD-1 Blockade, Camrelizumab, in Resectable Oral Squamous Cell 
Carcinoma 
Research Institutions: Department of Oral and Maxillofacial Surgery, School and Hospital of 
Stomatology, Wuhan University 
 
Dear patients: 
We invite you to participate in a clinical trial here. This informed consent form provides you 
with information to help you decide whether to participate in this clinical trial. Please read the 
following carefully for a while. If there are any questions or terms that are unclear, you can discuss 
it with your doctor. This study has been reviewed by the Ethics Committee of School and Hospital 
of Stomatology, Wuhan University. 
Background 
Oral squamous cell carcinoma is the most common tumor in the world. After surgery combined 
with radiotherapy and chemotherapy, patients with local advanced oral squamous cell carcinoma 
(OSCC) still have high recurrence and metastasis rates. At present, neoadjuvant immunotherapy 
researchs have achieved good results in other cancers, and the experimental studies of PD-1 mAb 
have also shown that it can significantly improve the survival rate of patients with advanced 
inoperable OSCC. Camrelizumab is a PD-1 inhibitor approved in China and has achieved good 
results in classic Hodgkin's lymphoma, esophageal cancer, hepatocellular carcinoma, non-small cell 
lung cancer, nasopharyngeal carcinoma and other diseases. As a new adjuvant, Camrelizumab is 
worthy of our in-depth study and evaluation of its role in resectable OSCC. 
Objects 
To clarify the safety and efficacy of camrelizumab combined with TPF chemotherapy as a 
neoadjuvant therapy for patients with local advanced OSCC, and to study the key molecular events 
and regulatory mechanisms in which patients can benefit from the above neoadjuvant therapy. To 
screen the liquid biopsy markers that can be used to accurately predict treatment effectiveness. 
Research process 
A total of 68 subjects will be enrolled in this trial were divided into two groups by 
randomization. One group received “camrelizumab + TPF chemotherapy, surgical resection and 
radiotherapy” sequence treatment; one group received “TPF chemotherapy, surgical resection and 
radiotherapy” sequence treatment. Follow-up will be performed every three months. If you have 
other special circumstances, you can return to the doctor at any time. 
Relevant examinations involved during the entire treatment period include: blood, saliva and 
tissue biopsy samples, imaging studies during treatment; blood and saliva collection every three 
months and semi-annual imaging studies during follow-up 
Risks and adverse reactions 
Adverse reactions caused by camrelizumab: Common adverse reactions include reactive 
capillary hemangioma, anemia, fever, fatigue, hypothyroidism, proteinuria and cough. There may 
be some risks and adverse reactions that are currently unpredictable. 
Adverse reactions caused by TPF chemotherapy: TPF chemotherapy may have 
myelosuppression, gastrointestinal reactions, liver and kidney dysfunction, cardiotoxicity, 
pulmonary fibrosis, and life-threatening if severe organ failure. 
Adverse reactions caused by surgery: Due to the patient's condition (critical, complicated, poor 

41 
 
systemic conditions), individual differences, sudden complications may occur during and after 
surgery, and multiple organ failure (such as heart failure, respiratory failure, liver failure, renal 
failure, DIC Etc.) or unpredictable changes in the condition can be life-threatening. 
Adverse reactions caused by radiotherapy: There will be loss of appetite, fatigue, local edema, 
dry mouth, odorlessness, restricted mouth or neck, radiation or skin or mucous membrane reaction, 
skin pigmentation. Due to the difference in tumor sensitivity to radiation, there may be exist 
insensitive for radiotherapy, tumor residual, and tumor recurrence. 
Benefits of participating 
If you agree to participate in this study, you will likely receive direct medical benefits, but may 
not benefit. We hope that the information from this study will be instructive in the future for patients 
with the same condition. 
In this study, you will receive a drug subsidy of up to 8,000 yuan and a transportation subsidy 
of 1,500 yuan. During this clinical study, if you are physically impaired or have a serious adverse 
event, you can get free treatment or get compensation according to the law. 
You may choose not to participate in this study, or have the right to withdraw at any stage of 
the trial without any reason, and your medical treatment and benefits will not be affected as a result. 
In addition to participating in this study, you have the following options: Surgical treatment, 
radiation (chemotherapy) treatment sequence therapy. 
Informed consent signature 
If you fully understand the content of this clinical trial and agree to participate in the study, you 
will sign this informed consent, in duplicate, by the investigator and the patient or the client. 
1. I confirm that I have read and understood the informed consent form of this study. The 
problems that may arise and the relative solutions have been explained to me, and I have the 
opportunity to ask my own questions. I have explicitly participated in the study as a voluntary act, 
and refusing to participate in the study will not harm any benefit I deserve. 
2. I have learned and agreed that the person in charge of this work at the School and Hospital 
of Stomatology, Wuhan University and the Medical Ethics Committee of the Wuhan University 
Stomatological Hospital have the right to review the research records and case data. I agree to 
provide the samples needed for clinical research for clinical trial studies. I agree that the above-
mentioned personnel can directly obtain my research records. 
 
Full name of patient                               Date 
 
Full name of legal representative                     Date 
 
Full name of researcher                             Date 
 
 
 
 
 
 
 

42 
 
References 
1. 
Uppaluri R, Zolkind P, Lin T, Nussenbaum B, Jackson RS, et al. Neoadjuvant pembrolizumab in 
surgically resectable, locally advanced HPV negative head and neck squamous cell carcinoma (HNSCC). 
Journal of Clinical Oncology. 2017; 35(15_suppl):6012-6012. 
2. 
Wise-Draper TM, Old MO, Worden FP, O'Brien PE, Cohen EEW, et al. Phase II multi-site 
investigation of neoadjuvant pembrolizumab and adjuvant concurrent radiation and pembrolizumab 
with or without cisplatin in resected head and neck squamous cell carcinoma. Journal of Clinical 
Oncology. 2018; 36(15_suppl):6017-6017. 
3. 
Zhong LP, Zhang CP, Ren GX, Guo W, William WN, Jr., et al. Randomized phase III trial of 
induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front 
surgery in locally advanced resectable oral squamous cell carcinoma. J Clin Oncol. 2013; 31(6):744-751.